Provenant AI Labs Contact

Healthcare · Pilot readiness

Align the people, systems and safeguards before a pilot begins.

A controlled pilot needs shared understanding across clinical, operational, IT, procurement, privacy and executive stakeholders.

A governed starting point

Make readiness visible before technology enters the workflow.

Medi AI+ is a pre-clinical R&D programme. Any future pilot discussion is subject to technical validation, institutional review, privacy and cybersecurity assessment, procurement, and applicable regulatory requirements.

Public information intentionally avoids proprietary architecture, internal implementation details and commercial terms.

Who should be involved

One readiness conversation. Six perspectives.

Each stakeholder group brings a different part of the operating boundary into view.

01

Clinical leadership

Define pilot boundaries, workflow suitability, escalation expectations, supervision and acceptance criteria.

02

IT & cybersecurity

Review network readiness, access controls, local data handling, device onboarding and security requirements.

03

Biomedical engineering

Coordinate device placement, peripheral readiness, power, physical setup, safety review and equipment workflows.

04

Data protection & compliance

Confirm privacy obligations, data minimisation, retention expectations, access governance and institutional approvals.

05

Procurement & operations

Review commercial process, timelines, site coordination, vendor onboarding and support expectations.

06

Executive sponsors

Align pilot goals with operational risk, patient safety, local AI adoption and deployment governance.

Disclosure boundary

Qualified conversations protect the work.

Appropriate materials may be shared with qualified stakeholders under agreed confidentiality, compliance and procurement processes.

Explore Medi AI+

Pilot & Regulatory Notice

Medi AI+ is currently a pre-clinical engineering programme. Product concepts and pilot configurations shown on this website are for stakeholder evaluation, controlled pilot planning, and qualified commercial discussion only. They are not represented as HSA-registered or approved medical devices, diagnostic systems, treatment systems, autonomous clinical decision-making, or substitutes for professional clinical judgement. It is not approved for diagnosis, treatment, or unsupervised clinical use. Any Singapore deployment must undergo appropriate institutional review, clinical governance, cybersecurity assessment, procurement checks, PDPA/data protection review, and, where applicable, Health Sciences Authority (HSA) medical-device classification, registration, licensing, and approval processes before clinical or operational use.